NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Cancer, Lentigo Maligna Melanoma

; ; .

Author Information

Last Update: May 18, 2019.

Introduction

Lentigo maligna (LM) is a subtype of melanoma, and commonly presents as an irregular brown macule on chronically sun-damaged skin, particularly the head and neck, in the elderly.[1] It was first described by Hutchinson in 1890 and referred to as “Hutchinson’s melanotic freckle.”[2] For much of the early 20th century, LM was thought to be either benign, infectious, or precancerous in nature due to its slow growth, with names given such as “junctional nevus,” “infective senile freckles,” and “circumscribed precancerous melanosis.”[2] It was not until the late 1970s-80s, spearheaded by research by Silvers,[3] Ackerman,[4] and colleagues, that LM became widely recognized as malignant. Today, LM is defined as melanoma in situ (MIS) on chronically sun-damaged skin.[5] Therefore by definition, LM is confined to the epidermis. If the lesion becomes invasive, it is termed lentigo maligna melanoma (LMM). Herein we review the key aspects of LM/LMM, as well as discuss the unique diagnostic and treatment challenges of this disease.

Etiology

The major risk factor for development of LM/LMM is ultraviolet radiation (UVR), in particular cumulative lifetime UVR exposure.[6][7][8][9] Several studies have demonstrated that LM/LMM is strongly associated with chronic UVR exposure, as opposed to nodular melanoma (NM) and superficial spreading melanoma (SSM) which are associated with intense intermittent UVR exposure.[7][8][9][10][11][12][13][14] An Australian study showed increased risk of LM with number of years lived in Australia, hours of sunlight, amount of actinic damage, and prior history of nonmelanoma skin cancer.[9] LM/LMM is also most likely to occur on the face, a site of chronic sun damage, whereas SSM and NM are more likely to occur on the trunk in men and legs in women, sites which are more often protected.[6] Finally, LM tends to occur in older patients compared to SSM and NM, presumably due to the increased lifetime sun exposure in older individuals.[15][16]

Aside from UVR, x-ray irradiation, estrogen/progesterone, and nonpermanent hair dyes have been suggested risk factors.[2] LM is also more likely to occur in genetic conditions that predispose to sun sensitivity, including oculocutaneous albinism, xeroderma pigmentosum, Werner syndrome, and porphyria cutanea tarda.[2] There have been no associations demonstrated with smoking or alcohol.[17]

Epidemiology

LM/LMM is the third most common subtype of melanoma (behind SSM and NM), comprising 4-15% of all melanomas and 10-26% of melanomas on the head and neck.[2] The mean age of diagnosis is 66-72 years,[14][18] compared to 45-57 years for other subtypes of melanoma.[19][20] Women are more often affected than men (ratio 1.7:1)[14] and are slightly older at diagnosis.[21]

The incidence of LM/LMM has been rising over the past few decades, with data from Olmstead County, Minnesota showing an increase from 2.2 cases/100,000 person-years between 1970-1989 to 13.7 cases/100,000 person-years between 2004-2007.[22] A similar rise in incidence was observed in the Netherlands.[23] Data from California showed a particularly rapid 52% rise in incidence among younger people ages 45-64 between 1990-2000.[18] It is unclear whether these data represent true increases in incidence or improved diagnosis.[24] The faster rise in incidence of MIS compared to invasive melanoma suggests that detection bias plays some role at least.[25]

Pathophysiology

Melanoma has one of the highest mutational loads of all malignancies,[26] and LM/LMM has an especially high mutation rate due to chronic UVR exposure.[27][28][29] UVR causes oxidative damage and produces signature C>T and CC>TT mutations,[30] which in turn alter genes involved in the MAPK and PI3K pathways including BRAF, NRAS, and KIT. Secondary mutations in CCND1, CDKN2A, and/or p53 then lead to transformation into malignant tumor.[31] LM/LMM is more likely to harbor mutations in KIT compared to other subtypes of melanoma, in which BRAF mutations are more common.[32][33][34] Mutations in CCND1, MITF, NRAS, and p53 also play a pathogenic role.[31]

Histopathology

LM is characterized by a proliferation of atypical melanocytes along the dermal-epidermal junction (DEJ). Early LM may be difficult to distinguish from benign changes of chronic solar damage, which also induces melanocytic hyperplasia.[35] For this reason, a control biopsy of non-lesional but sun-damaged skin is sometimes recommended.[36] Melanocytes are typically singly arranged, although nests and multinucleated cells may be seen. Pagetoid spread may occur, but less frequently than in superficial spreading melanoma. Periadnexal extension is common with involvement of the follicular outer root sheath and eccrine duct. The tumor cells often have a conspicuous cytoplasmic retraction artifact, and nuclei are often enlarged, hyperchromatic, and angulated. Background changes of chronic sun damage are usually present, including solar elastosis, epidermal atrophy, and effacement of the rete ridges. Pigmentation is variable but may be abundant, and the papillary dermis may contain melanophages. Lymphocytes are usually seen in the superficial dermis, although prominent lymphocytic inflammation may be a sign of tumor invasion and should therefore prompt closer examination. As LM becomes more invasive (i.e. progresses to LMM), junctional nests become larger and more spindled. Invasion is typically superficial, consisting of isolated or small aggregates of spindled cells in the papillary dermis. Desmoplasia and perineural invasion may occur, and the desmoplastic component may be mistaken for scar. Rarely, a storiform growth pattern may be present, which may be mistaken for dermatofibrosarcoma protuberans (DFSP).[2][37][38] Immunohistochemistry with MART-1/Melan-A, HMB-45, tyrosinase, MITF, Sox10, and S100 may aid in diagnosis.[2][36]

History and Physical

LM often presents as an irregular brown macule or patch on chronically sun-damaged skin in the elderly. Lesions are light-brown to black, may display color variegation, may be asymmetric, and tend to have an ill-defined border. As lesions enlarge, they may develop skip areas with a patchy, non-contiguous pattern. Lesions are usually asymptomatic, although advanced tumors may produce pain, burning, itching, or bleeding. The majority of cases (86%) occur on the head/neck, with predilection for the cheek.[2][21] Extrafacial cases tend to occur on the extremities in women and back in men.[21][39] Due to its in situ nature, LM is typically smooth and non-palpable. If the lesion becomes invasive (LMM), then a papular or dermal component may be felt. LM exhibits slow radial growth, and may be misdiagnosed for years or even decades as solar lentigo or other benign lesions (see Differential Diagnosis section).[5] The overall lifetime risk of progression from LM to LMM has been estimated to be 5% based on a retrospective epidemiologic study.[40] However, the true lifetime risk may be greater, as between 10-20% of cases that are initially diagnosed as LM on biopsy are later upstaged to LMM after excision.[41][42][43][44] The timeframe of progression to LMM varies widely, from less than 10 years to more than 50 years.[45][46]

Evaluation

The clinical findings on naked eye exam have been detailed above (see History and Physical section). Clinical diagnosis can be challenging due to overlapping features with benign lesions such as solar lentigo, pigmented actinic keratosis, and others. For this reason, optical imaging tools such as dermoscopy and more newly reflectance confocal microscopy (RCM) have been developed to aid in diagnosis.

Dermoscopic findings for LM/LMM reveal a stepwise progression of features based on degree of infiltration of the follicular ostia. Early lesions exhibit peppering of pigmentation around follicular ostia, known as annular-granular structures or blue-grey dots. As the lesion grows, the dots will coalesce to form short polygonal lines around and in between adnexal openings. Further progression of the tumor leads to merging and darkening of the polygonal lines into polyhedral shapes known as rhomboidal structures. Eventually, the tumor obliterates the entire follicular ostia and becomes a homogeneous dark brown to black blotch.[47][48][49][50]

RCM findings specific for LM/LMM are divided into major and minor criteria.[51] The two major criteria include nonedged papillae and round pagetoid cells > 20 µm. The three minor criteria include atypical cells at the DEJ, follicular localization of atypical cells, and nucleated cells within the dermal papillae. Although dermoscopy and RCM are important tools for diagnosis, skin biopsy for histopathologic examination remains the gold standard (see Histopathology section). Biopsy techniques can include excisional biopsy with narrow margins, incisional biopsy of the most atypical appearing or thickest portion of the lesion, or broad saucerization of the entire lesion being sure to obtain sufficient depth.[5] Finally, Wood’s lamp, dermoscopy, and RCM may help delineate surgical margins prior to excision.[52][53]

Treatment / Management

Surgical excision is the treatment of choice. Numerous studies have shown the traditional 0.5 cm surgical margins for MIS to be inadequate for LM, with approximately half of tumors requiring larger margins for clearance[36] and with recurrence rates between 8-20%.[54] The National Comprehensive Cancer Network (NCCN) in 2014 updated their guidelines to recommend 0.5-1.0 cm margins for MIS,[55] and several single-center studies have called for larger margins up to 1.0 cm or more.[41][56][57][58] A recent study by Zitelli and Brodland, in which they treated over 1500 cases of LM with Mohs micrographic surgery (MMS), demonstrated that 1.2 cm margins were required to achieve a 97% clearance rate.[56] Among surgical modalities, wide local excision (WLE) remains the standard of care based on expert panels.[59][60] However, there is a growing body of literature showing the MMS may be superior.[56][61][62][63] Several institutions that perform both MMS and WLE for LM have demonstrated recurrence rates of 1.8-1.9% using MMS and 5.8-5.9% using WLE.[61][63] In experienced hands and with the use of immunohistochemistry, recurrence rates with MMS can be as low as 0.3-0.5%.[56][64]

For patients who wish to avoid surgery or would otherwise be poor surgical candidates, topical imiquimod 5% cream may be a viable alternative, although the data on efficacy is mixed. Clinical and histologic clearance rates for imiquimod range between 46-78% and 37-76%, respectively.[65][66] Radiation therapy may also be an acceptable non-surgical option. The method and type of radiation varies, but most commonly fractionated superficial radiotherapy or Grenz rays is delivered. Recurrence rates have been reported to be between 5-14%.[67][68][69] Finally, many other non-surgical modalities have been reported with varying success, including laser ablation, cryotherapy, azelaic acid, 5-fluorouracil cream, and chemical peels, but the data are too sparse and inconsistent to draw any reliable conclusions.[2]

Differential Diagnosis

The clinical and dermoscopic differential diagnoses include solar lentigo, early/macular seborrheic keratosis, lichen planus-like keratosis (LPLK), and pigmented actinic keratosis. The histopathologic mimickers include benign melanocytic hyperplasia of sun-damaged skin, and for invasive lesions (LMM) include desmoplastic melanoma and rarely DFSP.

Staging

Staging for LM/LMM is the same as for all melanomas, using the TNM staging criteria based on the latest American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th Edition.[70] We would encourage readers to refer to that resource for an in-depth discussion. The stages are briefly summarized below:

  • Stage I – Low-risk primary melanomas (T1a, T1b, T2a) without evidence of regional or distant metastases.
  • Stage II – Primary melanomas that are at higher risk of recurrence (T2b, T3a, T3b, T4a, T4b), but without evidence regional or distant metastases.
  • Stage III – Involvement of regional lymph nodes or presence of in-transit or satellite metastases.
  • Stage IV – Distant metastases present.

Prognosis

The prognosis for LM/LMM excellent. In a study of 270 patients with LM/LMM that were completely excised, there were zero disease-related deaths for LM and only one for LMM.[71] The 5-year and 10-year disease-specific survival were 100% and 97.1%, respectively. Thus, LM in itself does not reduce lifespan. Once the tumor becomes invasive, however, the prognosis is the same as for all other melanomas after controlling for Breslow depth,[14] and can be potentially quite poor if the disease becomes metastatic (5-year survival 9-27%).[72] While mortality is low, morbidity for patients can be significant, given the potentially large surface area on the head/neck that may be involved and the need for extensive surgical excision and reconstruction.[73]

Deterrence and Patient Education

Due to the causative nature of chronic UVR damage in inducing LM/LMM, diligent sun protection is key to prevention. The American Academy of Dermatology (AAD) periodically publishes guidelines on the prevention and treatment of skin cancer.[59][74] Patients should wear broad-spectrum sunscreen (SPF ≥ 30) whenever outdoors, reapply every 2 hours and immediately after swimming, and use a sufficient amount (approximately 1 ounce or 1 shot-glass equivalent to cover the entire body). Wearing UPF clothing, avoiding the sun between peak hours of 10am-3pm, and seeking shade will provide additional sun protection. Finally, patients should be aware of the ABCDE criteria for melanoma, perform monthly skin self-examinations, and seek professional care by a dermatologist or primary care provider for any concerning lesions.

Pearls and Other Issues

LM/LMM presents diagnostic and treatment challenges due to its clinical mimicry of benign lesions, its occurrence on background sun-damaged skin thus confounding histopathologic differentiation between true tumor and benign melanocytic activation, and its occurrence on the head/neck, a cosmetically and functionally sensitive area. Thus maintaining clinical diligence and having a high index of suspicion is key to early diagnosis, in order to ensure optimal treatment outcomes and minimize morbidity and mortality for the patient. Surgical excision is the treatment of choice, with MMS emerging as a surgical option that may prove superior to WLE.

Enhancing Healthcare Team Outcomes

Providing optimal care for patients with LM/LMM requires a multidisciplinary approach. While dermatologists detect the majority of melanomas,[75] primary care physicians still play an important role in aiding in earlier detection, as they often serve as gatekeepers in managed care plans and frequently refer patients to dermatology.[76] Each additional family physician per 10,000 population has been associated with a 21% increased odds of early melanoma detection.[77] Once a lesion suspicious for LM/LMM is biopsied, having an experienced dermatopathologist can be invaluable for accurate diagnosis. Treatment of LM and early LMM may involve a multidisciplinary approach between the Mohs surgeon and other surgical specialists (e.g. plastics, oculoplastics, ENT) for excision and reconstruction. Finally, locally advanced or metastatic tumors should be referred to surgical oncology and hematology/oncology for appropriate staging and, if indicated, systemic therapy.

Questions

To access free multiple choice questions on this topic, click here.

References

1.
DeWane ME, Kelsey A, Oliviero M, Rabinovitz H, Grant-Kels JM. Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma. J. Am. Acad. Dermatol. 2019 Sep;81(3):823-833. [PubMed: 30930085]
2.
Kallini JR, Jain SK, Khachemoune A. Lentigo maligna: review of salient characteristics and management. Am J Clin Dermatol. 2013 Dec;14(6):473-80. [PubMed: 24019181]
3.
Cohen LM. Lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol. 1995 Dec;33(6):923-36; quiz 937-40. [PubMed: 7490362]
4.
Silvers DN. Focus on melanoma: the therapeutic dilemma of lentigo maligna (Hutchinson's freckle). J Dermatol Surg. 1976 Sep;2(4):301-3. [PubMed: 1026731]
5.
Dubow BE, Ackerman AB. Ideas in pathology. Malignant melanoma in situ: the evolution of a concept. Mod. Pathol. 1990 Nov;3(6):734-44. [PubMed: 2263599]
6.
Newell GR, Sider JG, Bergfelt L, Kripke ML. Incidence of cutaneous melanoma in the United States by histology with special reference to the face. Cancer Res. 1988 Sep 01;48(17):5036-41. [PubMed: 3409232]
7.
Elwood JM, Gallagher RP, Worth AJ, Wood WS, Pearson JC. Etiological differences between subtypes of cutaneous malignant melanoma: Western Canada Melanoma Study. J. Natl. Cancer Inst. 1987 Jan;78(1):37-44. [PubMed: 3467128]
8.
Elwood JM, Hislop TG. Solar radiation in the etiology of cutaneous malignant melanoma in Caucasians. Natl Cancer Inst Monogr. 1982;62:167-71. [PubMed: 7167183]
9.
Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J. Natl. Cancer Inst. 1984 Jul;73(1):75-82. [PubMed: 6588237]
10.
Holman CD, Armstrong BK, Heenan PJ. A theory of the etiology and pathogenesis of human cutaneous malignant melanoma. J. Natl. Cancer Inst. 1983 Oct;71(4):651-6. [PubMed: 6578359]
11.
Koh HK, Kligler BE, Lew RA. Sunlight and cutaneous malignant melanoma: evidence for and against causation. Photochem. Photobiol. 1990 Jun;51(6):765-79. [PubMed: 2195564]
12.
Schreiber MM, Moon TE, Bozzo PD. Chronic solar ultraviolet damage associated with malignant melanoma of the skin. J. Am. Acad. Dermatol. 1984 May;10(5 Pt 1):755-9. [PubMed: 6725671]
13.
Armstrong BK. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? J Dermatol Surg Oncol. 1988 Aug;14(8):835-49. [PubMed: 3397443]
14.
Cox NH, Aitchison TC, Sirel JM, MacKie RM. Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group. Br. J. Cancer. 1996 Apr;73(7):940-4. [PMC free article: PMC2074252] [PubMed: 8611411]
15.
McGovern VJ, Shaw HM, Milton GW, Farago GA. Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology. 1980 May;4(3):235-42. [PubMed: 7390408]
16.
Holman CD, Mulroney CD, Armstrong BK. Epidemiology of pre-invasive and invasive malignant melanoma in Western Australia. Int. J. Cancer. 1980 Mar 15;25(3):317-23. [PubMed: 7390655]
17.
Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. IV. No association with nutritional factors, alcohol, smoking or hair dyes. Int. J. Cancer. 1988 Dec 15;42(6):825-8. [PubMed: 3192325]
18.
Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J. Invest. Dermatol. 2005 Oct;125(4):685-91. [PubMed: 16185266]
19.
Lemish WM, Heenan PJ, Holman CD, Armstrong BK. Survival from preinvasive and invasive malignant melanoma in Western Australia. Cancer. 1983 Aug 01;52(3):580-5. [PubMed: 6861096]
20.
Gassenmaier M, Keim U, Leiter U, Eigentler TK, Röcken M, Gesierich A, Moritz RKC, Heinzerling L, Tüting T, Wollina U, Garbe C. Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. J. Am. Acad. Dermatol. 2019 May;80(5):1299-1307.e7. [PubMed: 30703453]
21.
Cox NH, Aitchison TC, MacKie RM. Extrafacial lentigo maligna melanoma: analysis of 71 cases and comparison with lentigo maligna melanoma of the head and neck. Br. J. Dermatol. 1998 Sep;139(3):439-43. [PubMed: 9767288]
22.
Mirzoyev SA, Knudson RM, Reed KB, Hou JL, Lohse CM, Frohm ML, Brewer JD, Otley CC, Roenigk RK. Incidence of lentigo maligna in Olmsted County, Minnesota, 1970 to 2007. J. Am. Acad. Dermatol. 2014 Mar;70(3):443-8. [PMC free article: PMC4527652] [PubMed: 24373777]
23.
Greveling K, Wakkee M, Nijsten T, van den Bos RR, Hollestein LM. Epidemiology of Lentigo Maligna and Lentigo Maligna Melanoma in the Netherlands, 1989-2013. J. Invest. Dermatol. 2016 Oct;136(10):1955-1960. [PubMed: 27349862]
24.
Higgins HW, Lee KC, Galan A, Leffell DJ. Melanoma in situ: Part I. Epidemiology, screening, and clinical features. J. Am. Acad. Dermatol. 2015 Aug;73(2):181-90, quiz 191-2. [PubMed: 26183967]
25.
Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer. 2005 Feb 01;103(3):616-24. [PubMed: 15630700]
26.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Imielinsk M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR, Australian Pancreatic Cancer Genome Initiative. ICGC Breast Cancer Consortium. ICGC MMML-Seq Consortium. ICGC PedBrain. Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415-21. [PMC free article: PMC3776390] [PubMed: 23945592]
27.
Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin. Cancer Res. 2013 Sep 01;19(17):4589-98. [PubMed: 23833303]
28.
Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001 Jan;12(1):69-82. [PubMed: 11227927]
29.
Davis EJ, Johnson DB, Sosman JA, Chandra S. Melanoma: What do all the mutations mean? Cancer. 2018 Sep 01;124(17):3490-3499. [PMC free article: PMC6191351] [PubMed: 29663336]
30.
Sanchez MI, Grichnik JM. Melanoma's high C>T mutation rate: is deamination playing a role? Exp. Dermatol. 2014 Aug;23(8):551-2. [PubMed: 24815223]
31.
Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239-71. [PMC free article: PMC4831647] [PubMed: 24460190]
32.
Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 2011 Apr;164(4):776-84. [PubMed: 21166657]
33.
Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J. Invest. Dermatol. 2005 Sep;125(3):575-9. [PubMed: 16117801]
34.
Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006 Sep 10;24(26):4340-6. [PubMed: 16908931]
35.
Weyers W, Bonczkowitz M, Weyers I, Bittinger A, Schill WB. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am J Dermatopathol. 1996 Dec;18(6):560-6. [PubMed: 8989926]
36.
McGuire LK, Disa JJ, Lee EH, Busam KJ, Nehal KS. Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast. Reconstr. Surg. 2012 Feb;129(2):288e-299e. [PubMed: 22286443]
37.
Green A, Little JH, Weedon D. The diagnosis of Hutchinson's melanotic freckle (lentigo maligna) in Queensland. Pathology. 1983 Jan;15(1):33-5. [PubMed: 6856341]
38.
Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod. Pathol. 2006 Feb;19 Suppl 2:S34-40. [PubMed: 16446714]
39.
Martínez-Leboráns L, Garcías-Ladaria J, Oliver-Martínez V, Alegre de Miquel V. Extrafacial Lentigo Maligna: A Report on 14 Cases and a Review of the Literature. Actas Dermosifiliogr. 2016 Oct;107(8):e57-63. [PubMed: 27180003]
40.
Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br. J. Dermatol. 1987 Mar;116(3):303-10. [PubMed: 3567069]
41.
Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast. Reconstr. Surg. 2009 Dec;124(6):1947-55. [PubMed: 19952650]
42.
Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J. Am. Acad. Dermatol. 2008 Jan;58(1):142-8. [PubMed: 18029055]
43.
Penneys NS. Microinvasive lentigo maligna melanoma. J. Am. Acad. Dermatol. 1987 Oct;17(4):675-80. [PubMed: 3312317]
44.
Somach SC, Taira JW, Pitha JV, Everett MA. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol. 1996 Nov;132(11):1297-302. [PubMed: 8915306]
45.
Jackson R, Williamson GS, Beattie WG. Lentigo maligna and malignant melanoma. Can Med Assoc J. 1966 Oct 22;95(17):846-51. [PMC free article: PMC1936829] [PubMed: 5922502]
46.
Clark WH, Mihm MC. Lentigo maligna and lentigo-maligna melanoma. Am. J. Pathol. 1969 Apr;55(1):39-67. [PMC free article: PMC2013384] [PubMed: 5776171]
47.
Cognetta AB, Stolz W, Katz B, Tullos J, Gossain S. Dermatoscopy of lentigo maligna. Dermatol Clin. 2001 Apr;19(2):307-18. [PubMed: 11556239]
48.
Bollea-Garlatti LA, Galimberti GN, Galimberti RL. Lentigo Maligna: Keys to Dermoscopic Diagnosis. Actas Dermosifiliogr. 2016 Jul-Aug;107(6):489-97. [PubMed: 26875792]
49.
Annessi G, Bono R, Abeni D. Correlation between digital epiluminescence microscopy parameters and histopathological changes in lentigo maligna and solar lentigo: A dermoscopic index for the diagnosis of lentigo maligna. J. Am. Acad. Dermatol. 2017 Feb;76(2):234-243. [PubMed: 28341252]
50.
Mataca E, Migaldi M, Cesinaro AM. Impact of Dermoscopy and Reflectance Confocal Microscopy on the Histopathologic Diagnosis of Lentigo Maligna/Lentigo Maligna Melanoma. Am J Dermatopathol. 2018 Dec;40(12):884-889. [PubMed: 29933314]
51.
Guitera P, Pellacani G, Crotty KA, Scolyer RA, Li LX, Bassoli S, Vinceti M, Rabinovitz H, Longo C, Menzies SW. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J. Invest. Dermatol. 2010 Aug;130(8):2080-91. [PubMed: 20393481]
52.
Chen CS, Elias M, Busam K, Rajadhyaksha M, Marghoob AA. Multimodal in vivo optical imaging, including confocal microscopy, facilitates presurgical margin mapping for clinically complex lentigo maligna melanoma. Br. J. Dermatol. 2005 Nov;153(5):1031-6. [PubMed: 16225620]
53.
Robinson JK. Use of digital epiluminescence microscopy to help define the edge of lentigo maligna. Arch Dermatol. 2004 Sep;140(9):1095-100. [PubMed: 15381550]
54.
Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg. 2002 Dec;55(8):611-5. [PubMed: 12550112]
55.
Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M., National Comprehensive Cancer Network. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May;12(5):621-9. [PubMed: 24812131]
56.
Kunishige JH, Doan L, Brodland DG, Zitelli JA. Comparison of surgical margins for lentigo maligna versus melanoma in situ. J. Am. Acad. Dermatol. 2019 Jul;81(1):204-212. [PubMed: 31014825]
57.
Jejurikar SS, Borschel GH, Johnson TM, Lowe L, Brown DL. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast. Reconstr. Surg. 2007 Oct;120(5):1249-55. [PubMed: 17898597]
58.
Bosbous MW, Dzwierzynski WW, Neuburg M. Lentigo maligna: diagnosis and treatment. Clin Plast Surg. 2010 Jan;37(1):35-46. [PubMed: 19914456]
59.
Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, Tsao H, Barbosa VH, Chuang TY, Duvic M, Ho VC, Sober AJ, Beutner KR, Bhushan R, Smith Begolka W., American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J. Am. Acad. Dermatol. 2011 Nov;65(5):1032-47. [PubMed: 21868127]
60.
Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr;14(4):450-73. [PubMed: 27059193]
61.
Nosrati A, Berliner JG, Goel S, McGuire J, Morhenn V, de Souza JR, Yeniay Y, Singh R, Lee K, Nakamura M, Wu RR, Griffin A, Grimes B, Linos E, Chren MM, Grekin R, Wei ML. Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision. JAMA Dermatol. 2017 May 01;153(5):436-441. [PMC free article: PMC5817486] [PubMed: 28241261]
62.
Beaulieu D, Fathi R, Srivastava D, Nijhawan RI. Current perspectives on Mohs micrographic surgery for melanoma. Clin Cosmet Investig Dermatol. 2018;11:309-320. [PMC free article: PMC6016488] [PubMed: 29950878]
63.
Hou JL, Reed KB, Knudson RM, Mirzoyev SA, Lohse CM, Frohm ML, Brewer JD, Otley CC, Roenigk RK. Five-year outcomes of wide excision and Mohs micrographic surgery for primary lentigo maligna in an academic practice cohort. Dermatol Surg. 2015 Feb;41(2):211-8. [PubMed: 25590473]
64.
Etzkorn JR, Sobanko JF, Elenitsas R, Newman JG, Goldbach H, Shin TM, Miller CJ. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J. Am. Acad. Dermatol. 2015 May;72(5):840-50. [PubMed: 25774012]
65.
Marsden JR, Fox R, Boota NM, Cook M, Wheatley K, Billingham LJ, Steven NM., NCRI Skin Cancer Clinical Studies Group, the U.K. Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study. Br. J. Dermatol. 2017 May;176(5):1148-1154. [PubMed: 27714781]
66.
Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J. Am. Acad. Dermatol. 2015 Aug;73(2):205-12. [PubMed: 26088690]
67.
Fogarty GB, Hong A, Scolyer RA, Lin E, Haydu L, Guitera P, Thompson J. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Br. J. Dermatol. 2014 Jan;170(1):52-8. [PubMed: 24032599]
68.
Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br. J. Dermatol. 2002 Jun;146(6):1042-6. [PubMed: 12072074]
69.
Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol. 1994 Aug;130(8):1008-12. [PubMed: 8053696]
70.
Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann. Surg. Oncol. 2018 Aug;25(8):2105-2110. [PubMed: 29850954]
71.
Gambichler T, Kempka J, Kampilafkos P, Bechara FG, Altmeyer P, Stücker M. Clinicopathological characteristics of 270 patients with lentigo maligna and lentigo maligna melanoma: data from a German skin cancer centre. Br. J. Dermatol. 2014 Dec;171(6):1605-7. [PubMed: 24958545]
72.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009 Dec 20;27(36):6199-206. [PMC free article: PMC2793035] [PubMed: 19917835]
73.
Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol. 2007 Oct;57(4):659-64. [PubMed: 17870430]
74.
Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J. Am. Acad. Dermatol. 2019 Jan;80(1):208-250. [PubMed: 30392755]
75.
Kantor J, Kantor DE. Routine dermatologist-performed full-body skin examination and early melanoma detection. Arch Dermatol. 2009 Aug;145(8):873-6. [PubMed: 19687416]
76.
Gerbert B, Maurer T, Berger T, Pantilat S, McPhee SJ, Wolff M, Bronstone A, Caspers N. Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Arch Dermatol. 1996 Sep;132(9):1030-8. [PubMed: 8795541]
77.
Roetzheim RG, Pal N, van Durme DJ, Wathington D, Ferrante JM, Gonzalez EC, Krischer JP. Increasing supplies of dermatologists and family physicians are associated with earlier stage of melanoma detection. J. Am. Acad. Dermatol. 2000 Aug;43(2 Pt 1):211-8. [PubMed: 10906640]
Copyright © 2019, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK482163PMID: 29489150

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...